eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2021
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

Influence of ursodeoxycholic acid therapy on levels of fibroblast growth factor 21, adiponectin and biochemical parameters in intrahepatic cholestasis of pregnancy

Michał Kukla
1, 2
,
Rafał Kierach
3
,
Magdalena Skonieczna
4, 5
,
Dorota Hudy
4, 5
,
Krzysztof Dąbrowski
3
,
Tomasz Menżyk
6
,
Aleksandra Derra
7
,
Dariusz Boroń
8, 9, 10
,
Beniamin Oskar Grabarek
8, 10

  1. Department of Gastroenterology and Hepatology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Poland
  2. Department of Endoscopy, University Hospital in Cracow, Poland
  3. Gynecology and Obstetrics Ward District Railway Hospital in Katowice, Poland
  4. Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland
  5. Biotechnology Centre, Silesian University of Technology, Gliwice, Poland
  6. Department of Internal Medicine, Gastroenterology and Acute Intoxication, Regional Hospital, Tarnów, Poland
  7. Department of Neurology, Medical Centre of Upper Silesia, Katowice, Poland
  8. Department of Histology, Cytophysiology and Embryology in Zabrze, University of Technology, Faculty of Medicine, Katowice, Poland
  9. Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Kraków, Poland
  10. District Hospital in Chrzanow, Poland
Clin Exp HEPATOL 2021; 7, 1: 13-24
DOI: https://doi.org/10.5114/ceh.2021.104419
Online publish date: 2021/03/25
View full text Get citation
 
PlumX metrics:
The aim was to assess whether fibroblast growth factor 21 (FGF-21) and adiponectin influence intrahepatic cholestasis of pregnancy (ICP) pathogenesis and whether ursodeoxycholic acid (UDCA) has an impact on their levels. 50 pregnant women with ICP (ICP PW), 50 with uncomplicated pregnancy (HPW) and 50 healthy nonpregnant women (HW) were included. In ICP PW the first blood sample was drawn at the time of diagnosis, while in HPW it was drawn in the 28th week of pregnancy. The next blood samples were drawn in the 32nd and 36th week of pregnancy and one day after delivery. UDCA was administered when ICP was diagnosed. In ICP PW serum FGF-21 concentration was the lowest at the time of diagnosis with an evident increase after UDCA administration. Serum FGF-21 levels were significantly higher in ICP PW than in HPW from the first to the last measurement. There was a negative association between adiponectin and bile acids (BAs) levels in the later stage of pregnancy in ICP PW. Up-regulated FGF-21 serum levels in ICP patients compared to HPW persisted after delivery, suggesting its role in disease pathophysiology. The negative association between serum adiponectin and BAs of the later stage of pregnancy may suggest its role in regulation of BAs concentration. UDCA exerts a beneficial effect on insulin sensitivity and up-regulates FGF-21 in ICP.
keywords:

adiponectin, fibroblast growth factor 21, insulin resistance, intrahepatic cholestasis of pregnancy, ursodeoxycholic acid, bile acids
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.